Harnessing the power of Imaging Phenomics

We’re transforming the science of medical imaging. By harnessing the power of Imaging Phenomics we can improve current treatment, enhance diagnosis and accelerate development of next generation therapies, helping make a healthier world for millions.

iBiopsy

Pushing the boundaries of imaging technology

We’re determined to push the boundaries of what imaging technology can achieve, to help develop next generation treatments with the potential to save or improve the lives of millions.

Clinical trial imaging

We deliver on a global scale

The combination of Median’s ground-breaking technology and world-class expertise perfectly positions us to revolutionize the field of medical imaging, transforming data generation, management, and access all around the world. Benefiting patients, health professionals, our partners and investors.

Investors

The Imaging Phenomics Company®

Learn more about iSee®, our platform for the management of images in oncology clinical trials  and iBiopsy®, our imaging phenomics platform combining Artificial Intelligence, Cloud Computing and Big Data.

Watch

News

8 October 2019

Median Technologies’ Q3 performance shows steady growth, validates the strategy adopted in 2018 (unaudited figures)

Median Technologies’ Q3 performance shows steady growth, validates the strategy adopted in 2018 (unaudited figures). As of September 30th, 2019, cumulated revenue of € 6.3 million, already matching total revenue made in 2018 – Q3 revenue of € 2.3 million, a steady increase over the last four quarters – Order backlog of € 35.9 million, up 17% since June 30th, 2019 – Cash and cash equivalents of € 8.3 million, an increase compared to June 30th, 2019

3 October 2019

Median Technologies reports its financial results for H1 2019

Median Technologies reports its financial results for H1 2019. H1 revenue up 19.5% to € 4 million, driven by iCRO business, Order backlog up 30% to € 30.7 million, Significant decrease of operating expenses, Cash and cash equivalents of € 7.9 million

11 July 2019

Median Technologies Announces Preliminary H1 2019 Unaudited Financial Results

H1 2019 results validate the company’s 2018 strategic refocus. During the period, revenues increased by 19,6% to reach €4 million (€3.4 million in H1 2018). Net new booking reached €11 million and order backlog increased by 30% to €30.7 million (€23.7 million as of December 31, 2018). Cash and cash equivalents expected to be approximatively €7.9 million as of June 30, 2019, with significantly reduced burn rate.

8 July 2019

AG Mednet and Median Technologies Partnership Supports Global Clinical Trials Portfolio, Including Extensive Programs in China

Median Technologiesand AG Mednet have renewed their partnership to use AG Mednet’s global infrastructure for the collection, QC and delivery of medical images and ancillary data in support current and future clinical trials and programs. Median provides solutions and services for medical image analysis and management in oncology trials globally. AG Mednet works with global CROs, providing technology solutions for clinical trial adjudication and imaging.

28 June 2019

Financial Communications Schedule for the Second Half of 2019

Median Technologies (Paris:ALMDT), The Imaging Phenomics Company®, announces the publication date for its half year results 2019.

1/5
Imaging for clinical trials

Advancing treatments of the future

Working with biopharma companies and leading medical centers around the world, the team at Median enable researchers to identify disease fingerprints from medical images. We’re helping paving the way for new personalized and innovative medicines, more accurate and predictable diagnoses and better treatments.

Read more

Ibiopsy®

Powering the phenomics revolution

We’re changing the game, transforming the landscape. We’re capturing the power of big data, cloud computing and artificial intelligence to create a new world of possibilities for biopharma compannies and healthcare professionals alike. Our iBiopsy® platform opens up the field of phenomics, driving the science of precision and predictive medicine.

Read more

Investors

Delivering value

Our technology and expertise is creating a new world of possibilities for biopharmaceutical and healthcare professionals around the world. By successfully helping improve the lives of millions, we are also delivering value for our investors and partners.

Read more

Stock Market Data

TICKER: ALMDT ISIN: FR0011049824
Get in touch

Together, let's build the future of medicine

Contact us Jobs at Median